- Conditions: Colles Fracture; Point of Care Ultrasound; Emergency Ultrasound
Intervention: Device: Point of care ultrasound
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012 - Condition: Cardiac Sarcoidosis
Intervention:
Sponsors: University of Ottawa Heart Institute; University of Ottawa Heart Institute; Ontario Ministry of Health and Long Term Care
Not yet recruiting - verified December 2011 - Conditions: Prediabetes; Prehypertension
Intervention: Behavioral: Health Coaching
Sponsors: Memorial University of Newfoundland; Marshal Godwin; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified October 2011 - Condition: Atherosclerosis
Intervention:
Sponsors: Canadian Atherosclerosis Imaging Network; Canadian Atherosclerosis Imaging Network; Canadian Institutes of Health Research (CIHR)
Recruiting - verified July 2011 - Condition: Gestational Hypertension
Interventions: Procedure: Intervention is blood pressure management approach; Procedure: Intervention is blood pressure management approach.
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR); Sunnybrook Research Institute
Recruiting - verified December 2011 - Condition: Lung Cancer
Interventions: Drug: PF-00299804; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Conditions: Psoriasis; Atopic Dermatitis
Interventions: Other: Blood pressure; Other: Height; Other: Weight; Other: BMI; Other: Waist Circumference
Sponsors: Northwestern University; Northwestern University
Recruiting - verified September 2011 - Condition: Chronic Kidney Disease
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Active, not recruiting - verified November 2011 - Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified November 2011 - Condition: Cystic Fibrosis
Interventions: Other: Positive Expiratory Pressure (PEP); Other: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System
Sponsors: University of British Columbia; University of British Columbia; Canadian Cystic Fibrosis Foundation
Active, not recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG); Cancer and Leukemia Group B
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: brivanib alaninate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Condition: Cystic Fibrosis
Interventions: Drug: azithromycin 250 mg tablets; Drug: placebo tablets
Sponsors: CF Therapeutics Development Network Coordinating Center; CF Therapeutics Development Network Coordinating Center; Cystic Fibrosis Foundation
Completed - verified February 2012 - Condition: Lung Cancer
Intervention: Radiation: 3-dimensional conformal radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: CHOP regimen
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified August 2011 - Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Biological: epoetin alfa; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified May 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); AGO Study Group; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Sarcoma
Intervention: Drug: alvocidib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012 - Condition: Hodgkin Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: vinblastine; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group
Completed - verified January 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: melphalan; Drug: prednisone
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Lung Cancer
Interventions: Drug: marimastat; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Condition: Endometrial Cancer
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified April 2012
 |
Join Clinical Trials by University in Newfoundland |
